Immunocore Limited

Emma Elizabeth Baston

Andrew Creese

Viren Vinubhai Patel

Luis Filipe Da Silva Godinho

Pranav Bheamadu

Praveen Singh

Ruth Martinez Hague

Marcin Dembek

Andrew Alexander Knox

Jonathan Patrick Lowther

Fiona Chester

Thomas Minshull

Specific binding molecules, including T cell receptors (TCRs), which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17 are presented. TCRs of the present invention comprise non-natural mutations within the alpha and/or beta variable domains relative to a native TCR. The specific binding molecules of the invention have improved stability and/or yield and yet unexpectedly retain the advantageous properties of the specific binding molecules from which they are derived. Such specific binding molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of HIV infected individuals.

HIV specific binding molecules

The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLLMWITQC derived from the cancer antigen NY-ESO-1. Said TCRs may comprise mutations within the alpha and/or beta variable domains relative to a native NY-ESO-1 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.

T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex

Growing community of inventors

Abingdon, United Kingdom

Emma Elizabeth Baston